Selank – 10mg

The breakout anxiolytic peptide of modern neuroscience research — and one of the most intriguing compounds in the Russian regulatory peptide tradition. Selank sits at a unique intersection: anxiolytic activity without sedation or dependence, combined with immunomodulatory effects that reflect its tuftsin lineage. A compound with a genuinely distinct research profile.

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin, with a C-terminal Pro-Gly-Pro extension that boosts its stability. It works through multiple pathways: modulation of GABAergic signalling without direct benzodiazepine-receptor binding, influence on serotonergic and noradrenergic systems, and inhibition of enkephalin enzymatic degradation. Research has also documented effects on cytokine expression and BDNF-related signalling — positioning it right at the intersection of anxiolytic and immunomodulatory research.

Selank is authorised as a medicine in Russia for anxiety-related indications, with a Russian-language clinical literature spanning several decades. Independent Western clinical trials and broader regulatory authorisation are limited. It remains a research compound of significant interest in anxiolytic and immunomodulatory studies.

Published studies — concentrated in Russian-language literature — have explored:
Anxiolytic activity: Clinical studies in generalised anxiety disorder cohorts, with reported effects comparable to benzodiazepines but without sedation or dependence patterns.
Cognitive effects: Studies on attention, memory, and cognitive performance in clinical and healthy cohorts.
Immunomodulation: Effects on cytokine expression and immune function, reflecting its tuftsin lineage.
Enkephalin biology: Mechanistic research on endogenous opioid system modulation.